Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide versus rituximab in children with steroid-resistant nephrotic syndrome
IRCT20170527034146N2Phase 2Completed
- Sponsor
- Qom University of Medical Sciences
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cyclophosphamide and rituximab in nephrosis (2 arms), sponsored by Qom University of Medical Sciences. Primary endpoints: Frequent relapses and Steroid dose. Started Sep 2017; status: completed.
02
Drugs
cyclophosphamiderituximab
03
Conditions
nephrosis
Beyond the preview
Go deeper on IRCT20170527034146N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170527034146N2.